Escitalopram in the treatment of obsessive–compulsive disorder

References

• Heyman I, Mataix-Cols D, Fineberg NA. Obsessive–compulsive disorder. Br. Med. J.333, 424–429 (2006).
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive–compulsive disorder. Int. J. Neuropsychopharmacol.8, 107–129 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 593–602 (2005).
   PubMed Web of Science ®Google Scholar
• Weissman MM, Bland RC, Canino GJ et al. The cross national epidemiology of obsessive compulsive disorder. The cross national collaborative group. J. Clin. Psychiatry55(Suppl.), 5–10 (1994).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association, Washington, DC, USA (1994).
   Google Scholar
• Stein DJ. Obsessive–compulsive disorder. Lancet360, 397–405 (2002).
   PubMed Web of Science ®Google Scholar
• Hollander E, Kim S, Khanna S, Pallanti S. Obsessive–compulsive disorder and obsessive–compulsive spectrum disorders: diagnostic and dimensional issues. CNS Spectr.12(2 Suppl. 3), 5–13 (2007).
   Web of Science ®Google Scholar
• Zohar J, Hollander E, Stein DJ, Westenberg HGM, and the Cape Town Consensus Group. Consensus statement. CNS Spectr.12(2 Suppl. 3), 59–63 (2007).
   Google Scholar
• Montgomery S, Zohar J. Obsessive Compulsive Disorder. ©Martin Dunitz Ltd, London, UK (1999). (Translations: Japanese and Spanish).
   Google Scholar
• Stein DJ, Ipser JC, Baldwin DS, Bandelow B. Treatment of obsessive–compulsive disorder. CNS Spectr.12(2 Suppl. 3), 28–35 (2007).
   Web of Science ®Google Scholar
• El Mansari M, Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive–compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry30, 362–373 (2006).
   PubMed Web of Science ®Google Scholar
• Zohar J, Kennedy JL, Hollander E, Koran L. Serotonin-1D hypothesis of obsessive–compulsive disorder: an update. J. Clin. Psychiatry65(Suppl. 14), 18–21 (2004).
   PubMed Web of Science ®Google Scholar
• Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine and obsessive–compulsive disorder: further evidence for a serotonergic mechanism of action. Arch. Gen. Psychiatry46, 23–28 (1989).
   PubMed Web of Science ®Google Scholar
• Zohar J, Fostick L, Sonnino R, Harari E, Sasson Y. Antipsychotics in OCD. In: Obsessive Compulsive Disorder and Comorbidity. Gross-Isseroff R, Weizman A (Eds). Nova Science Publishers, NY, USA, 131–144 (2006).
   Google Scholar
• Denys D, Zohar J, Westenberg H. The role of dopamine in obsessive–compulsive disorder: preclinical and clinical evidence. J. Clin. Psychiatry65(Suppl. 14), 11–17 (2004).
   PubMed Web of Science ®Google Scholar
• Geller D, Biederman J, Stewart S et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive–compulsive disorder. Am. J. Psychiatry160(11), 1919–1928 (2003).
   PubMed Web of Science ®Google Scholar
• Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive–compulsive disorders. J. Clin. Psychiatry60(2), 101–106 (1999).
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Saxena S, Zohar J, Craig KJ. Obsessive–compulsive disorder: boundary issues. CNS Spectr.12(5), 359–364, 367–375 (2007).
   PubMed Web of Science ®Google Scholar
• Samuels J, Bienvenu OJ, Riddle MA et al. Hoarding in obsessive compulsive disorder: results from a case control study. Behav. Res. Ther.40(5), 517–528 (2002).
   PubMed Web of Science ®Google Scholar
• Rosario-Campos MC, Leckman JF, Mercadante MT et al. Adults with early-onset obsessive–compulsive disorder. Am. J. Psychiatry158, 1899–1903 (2001).
   PubMed Web of Science ®Google Scholar
• Fabre V, Hamon M. Mechanisms of action of antidepressants: new data from Escitalopram. [In French]. Encephale29(3), 259–265 (2003).
   PubMedGoogle Scholar
• Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl.)174, 163–176 (2004).
   PubMed Web of Science ®Google Scholar
• Zohar J, Schatzberg AF and DeBattista C. The International Black Book of Psychotropic Dosing and Monitoring. MBL Communications, NY, USA (2006).
   Google Scholar
• Burke WJ, Gergel I, Bose AA. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry63, 331–336 (2002).
   PubMed Web of Science ®Google Scholar
• Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol.17(3), 95–102 (2002).
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol.18, 211–217 (2003).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry64(11), 1322–1327 (2003).
   PubMed Web of Science ®Google Scholar
• Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomized, placebo-controlled, flexible-dosage study. Br. J. Psychiatry186, 222–226 (2005).
   PubMed Web of Science ®Google Scholar
• Lader M, Stender K, Bürger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomized, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety19(4), 241–248 (2004).
   PubMed Web of Science ®Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord.87(2–3), 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson JRT, Bose A, Korotzer A, Zheng HGM. Escitalopram in the treatment of generalized anxiety disorder: a double-blind, placebo controlled, flexible dose study. Depress. Anxiety19, 234–240 (2004).
   PubMed Web of Science ®Google Scholar
• Davidson JRT, Bose A, Su G. Escitalopram in the treatment of generalized anxiety disorder. Presented at: 22nd National Conference of the Anxiety Disorders Association of America, Austin, TX, USA 21–24 March 2002.
   Google Scholar
• Baldwin DS, Huusom AK, Mæhlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Br. J. Psychiatry189, 264–272 (2006).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol.9, 495–505 (2006).
   PubMed Web of Science ®Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int. Clin. Psychopharmacol.19, 149–155 (2004).
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry39, 180–184 (2006).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci.31(2), 122–131 (2006).
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol.20, 131–137 (2005).
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Privitera W, Ventura D, Bose A, Lenz SM, Wang Q. Fixed dose of escitalopram (10 mg/day) and a flexible dosing regimen of sertraline (50–200 mg/day) in a randomized, double blind comparison in depressed patients. Presented at: 1st International Congress of Biological Psychiatry. Sydney, Australia 9–13 February 2004.
   Google Scholar
• Boulenger J-P, Huusom AKT, Florea I, Bækdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr. Med. Res. Opin.22(7), 1331–1341 (2006).
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Bose A, Chang C-C. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry17(2), 65–69 (2005).
   PubMedGoogle Scholar
• Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin.23(4), 701–711 (2007).
   PubMed Web of Science ®Google Scholar
• Chen F, Larsen MB, Sánchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol.15(2), 193–198 (2005).
   PubMed Web of Science ®Google Scholar
• Søgaard B, Mengel H, Rao N, Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J. Clin. Pharmacol.45, 1400–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br. J. Clin. Pharmacol.60(3), 287–290 (2005).
   PubMed Web of Science ®Google Scholar
• Rao N. The clinical pharmacokinetics of escitalopram. Clin. Pharmacokinet.46(4), 281–290 (2007).
   PubMed Web of Science ®Google Scholar
• Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Ther.25(4), 1200–1210 (2003).
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Giancarlo GM, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Disp.29, 1102–1109 (2001).
   PubMed Web of Science ®Google Scholar
• Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin.23(4), 701–711 (2007).
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents relapse of obsessive–compulsive disorder. Eur. Neuropsychopharmacol.17(6–7), 430–439 (2007).
   PubMed Web of Science ®Google Scholar
• Möller H-J, Langer S, Schmauß M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry40, 53–57 (2007).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress. Anxiety21, 26–32 (2005).
   PubMed Web of Science ®Google Scholar
• Olié JP, Tonnoir B, Menard F, Galinowski A. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress. Anxiety24(5), 318–324 (2007).
   PubMedGoogle Scholar
• Galvão-de Almeida A, Quarantini LC, Góis CR et al. Obsessive–compulsive disorder: an open-label pilot trial of escitalopram. CNS Spectr.12(7), 519–524 (2007).
   PubMedGoogle Scholar
• Lexapro (escitalopram oxalate) tablets/oral solution, prescribing information. Forest Pharmaceuticals Inc. (May 2007).
   Google Scholar
• Hollander E, Bienstock CA, Koran LM et al. Refractory obsessive–compulsive disorder: state-of-the-art treatment. J. Clin. Psychiatry63(Suppl. 6), 20–29 (2002).
   PubMed Web of Science ®Google Scholar